PT3:03 Rapid Oral glucocorticoid discontinuation or dose reduction among US patients with SLE receiving belimumab in a real-world setting

Objectives Belimumab (BEL), a B-cell modulator mAb that selectively inhibits soluble B-lymphocyte stimulator and reduces autoreactive B cells driving lupus disease activity, is approved for adult and paediatric SLE and LN. 1 Prolonged oral glucocorticoids (OGC) can lead to organ damage, and real-world data demonstrate reduced OGC use with BEL. Here, we identified characteristics predicting early responses to BEL by OGC reduction or discontinuation among US patients with SLE.Methods This retrospective, longitudinal cohort study (GSK Study 222157) of health record data (Specialty Networks) included adults with SLE initiating subcutaneous (SC)/intravenous (IV) BEL (9/1/2011–4/25/2024; ‘index’) with clinical activity >=12 months pre-index (‘baseline period’) and >=10 months post-index and >=1 OGC prescription with dose information (prednisone-equivalent) and no baseline discontinuation. Exposure required >=1 SC/IV (SC BEL) or >=1 SC or >=2 IV (IV BEL) BEL records =50% or discontinuation (>=120 consecutive days without supply) =50% OGC dose reduction or discontinuation was achieved by 50.8% (n=275) in